Cite
HARVARD Citation
You, B. et al. (2023). CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study. Journal of clinical oncology. 41 (1), pp. 107-116. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
You, B. et al. (2023). CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study. Journal of clinical oncology. 41 (1), pp. 107-116. [Online].